 |
|
|
"We found that the risk of cancer was reduced with increased dose," said lead author Dr Cristina Bosetti (PhD), head of the Unit of Cancer Epidemiology at the Mario Negri Department of Oncology, Milan (Italy) in a press release. "An aspirin dose between 75 and 100mg a day was associated with a 10% reduction in a person's risk of developing cancer compared to people not taking aspirin; a dose of 325mg a day was associated with a 35% reduction, and a dose of 500mg a day was associated with a 50% reduction in risk."
Published in the Annals of Oncology April 16, 2020, the Italian researchers analyzed data from 113 observational studies published up to 2019, including 45 studies focused on bowel cancers involving 156,000 people. In addition, the studies examined data collected on cancers of the head and neck, esophagus, liver, gallbladder and pancreas. The study was funded by a grant from Bayer AG.
The data analysis showed that regular aspirin use, defined as taking at least one or two tablets a week, was associated with significant reductions in the the risk of developing all of those cancers, except head and neck cancer.
Specifically aspirin use was linked to a 27 percent reduction in bowel cancer, 33 percent reduction in esophageal cancer, 39 percent reduction in cancer of the gastric cardia, the tissues surrounding the opening of the throat where it empties into the stomach. There was also a 38 percent reduction in hepto-biliary (liver) cancer and a 22 percent lower risk of pancreatic cancer.
No comments:
Post a Comment